In Segment C, members will acquire ABBV-744 and oral navitoclax. In Phase D, members will get ABBV-744 and ruxolitinib. Members will obtain treatment till ailment progression or perhaps the individuals are not able to tolerate the study drugs. - "Our study disclosed the critical role with the KLF16/MYC regulatory axis https://elliotrepzk.ageeksblog.com/31076311/getting-my-abbv-744-brd4-inhibitor-clinical-efficacy-in-refractory-cancers-to-work